XTR003

Sinotau Pharmaceutical Group · Phase 2 active Small molecule

At a glance

Generic name	XTR003
Sponsor	Sinotau Pharmaceutical Group
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy (PHASE2)
XTR003 PET Radiotracer for the Detection of Viable Myocardium (PHASE2)
A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XTR003 CI brief — competitive landscape report
XTR003 updates RSS · CI watch RSS
Sinotau Pharmaceutical Group portfolio CI